68
E. Brenna et al. / Journal of Molecular Catalysis B: Enzymatic 101 (2014) 67–72
Scheme 1. Cyano-substituted unsaturated esters subjected to ER-mediated reduc-
tion (Ref. [6a] for (E)- and (Z)-1; Ref. [6b] for (E)- and (Z)-2).
On the basis of our experience on substrates 1, we decided to
investigate in more detail the stereochemistry of the bioreduction
of compounds 2 and to establish whether the nitrile or the ester
function acted as the activating group of the bioreduction, i.e. to
determine which of the two EWGs was involved in the formation
of hydrogen bonds with the amino acid residues in the active site
of OYE1-3.
As a matter of fact, this information is essential to define the
binding mode of the substrate, and identify the stereoheterotopic
face of the alkene moiety on which the H+ or H− is delivered for
the formation of the new stereogenic centre. Under the practi-
cal point of view, it is useful to identify the structural requisites
influencing this arrangement, in order to achieve the control on
the final stereochemical outcome of the reaction through a guided
substrate-engineering strategy.
The results obtained from this study have been also used to bet-
ter define the empirical model we have recently developed [6a] to
rationalise the experimental data on OYE1-3 mediated reductions
of activated alkenes, and to describe the structural prerequisites for
the optimal arrangement of the substrates within the binding site
of the enzymes. A distinction could be made between trisubstituted
alkenes for which the activating EWG was linked to the prostere-
ogenic carbon atom, and those activated by the other functional
group.
Scheme 2. Synthesis of cyanoesters (E)-2. Reagents and conditions: (i) Me3SiCN,
DMSO-water 5:1; (ii) SOCl2, Py, 100 ◦C; (iii) cyanoacetic acid, cat. NH4OAc in toluene;
(iv) NaBH4 in water and NaHCO3; and (v) CHOCOORꢀ, Ac2O, Py.
2.3. Bioreduction procedure for the preparation of
monodeuterated samples
A solution of the substrate in i-PrOH (100 L, 500 mM) was
added to potassium phosphate buffer solution (5.0 mL, 50 mM in
D2O, pH 7.0) containing glucose (20 mol), NADH (75 mol) and
the required OYE (1.11 M). The mixture was incubated for 24 h in
an orbital shaker (160 rpm, 30 ◦C). The solution was extracted with
EtOAc (3× 5.0 mL), centrifuging after each extraction (3000 × g,
drous Na2SO4.
3. Results and discussion
2. Experimental
The known data [6b] of the bioreductions of compounds 2 can
be summarised as follows. The best values of conversion and enan-
tioselectivity were achieved by using OYE1-3. (E)-stereoisomers
were generally converted into (S)-reduction products with high
enantioselectivity, whereas the conversion of (Z)-cyano esters into
the corresponding (R)-enantiomers decreased with the increasing
steric demand of the substrates. Reducing the size of the ester
moiety from ethyl to methyl had a strong positive impact on con-
versions, thus suggesting activation due to the ester group. An
interesting case of exceptional behaviour of OYE3 was observed
as for the enantioselectivity of the reduction of the cyano ester
precursor of pregabalin.
We decided to start a systematic investigation of the stereo-
chemical course of these reactions, by preparing other substrates
of type 2, showing (E) stereochemistry at the double bond and
increasing steric hindrance either at the ester moiety (2a–d) or
at the prostereogenic olefinic carbon atom (2e–h). Compound 2i
was also prepared to investigate the peculiar enantioselectivity of
that described in ref. 6b, in order to optimise the preparation of
(E)-stereoisomers of cyano esters 2. Derivatives (E)-2a–e were syn-
thesised starting from the corresponding -keto ester according to
route 1 (Scheme 2) which afforded only the desired configuration of
the C C double bond. Route 2 was employed to obtain compounds
(E)-2f–i, which were recovered from the reaction mixture and sep-
arated from the (Z)-stereoisomer by column chromatography.
The absolute configuration of the reduced products was deter-
mined by conversion either in the dimethyl ester or in the diacid
derivatives (by treatment with refluxing methanol and a catalytic
2.1. General procedure for OYE1–3 mediated biotransformations
of substrates (E)-2a–i (screening)
A solution of the substrate in DMSO (10 L, 500 mM) was
added to a potassium phosphate buffer solution (1.0 mL, 50 mM,
pH 7.0) containing glucose (20 mol), NADP+ (0.1 mol), GDH
(4 U) and the required OYE (0.89 M). The mixture was incubated
for 24 h in an orbital shaker (160 rpm, 30 ◦C). The solution was
extracted with EtOAc (2× 250 L), centrifuging after each extrac-
tion (15,000 × g, 1.5 min), and the combined organic solutions were
dried over anhydrous Na2SO4. Two replicates were performed for
each biotransformation: no significant differences were observed
for conversion and enantiomeric excess values.
2.2. General procedure for OYE1–3 mediated biotransformations
(50 mg scale)
For substrates (E)-2a–h a similar protocol was followed on a
larger scale, employing the OYE which provided the best conversion
and/or ee, in order to isolate and characterise the correspond-
ing reduced product. A solution of the suitable cyano ester in
i-PrOH (1 mL, 250 mM) was added to a potassium phosphate buffer
solution (25 mL, 50 mM, pH 7.0) containing the required OYE
(0.89–2.66 M), GDH (100 U), glucose (1 mmol, 180 mg) and NADP+
(5 mol, 3.7 mg). The reaction was monitored by GC until complete
conversion. The mixture was then extracted with EtOAc (3× 10 mL)
and submitted to column chromatography (n-hexane with increas-
ing amount of EtOAc), when conversion was not complete in order
to purify the reduced product from the starting material.